Trial Profile
Effects of the PCSK9 Antibody AliroCuMab on Coronary Atherosclerosis in PatieNts With Acute Myocardial Infarction: A Serial, Multivessel, Intravascular Ultrasound, Near-Infrared Spectroscopy And Optical Coherence Tomography Imaging Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary)
- Indications Coronary arteriosclerosis; Myocardial infarction; Stroke
- Focus Therapeutic Use
- Acronyms PACMAN-AMI
- 28 Aug 2023 Results assessing the influence of aggressive LDL-lowering on neutrophil activation, and immune cell gene expression of pro-inflammatory markers in a subset of the PACMAN-AMI cohort, presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology.
- 28 Aug 2023 Results assessing the effects of the PCSK9 inhibitor alirocumab on QFR and 3D-Quantitative Coronary Angiography (3D-QCA) DS% in non-infarct-related arteries (non-IRA) among acute myocardial infarction (AMI) patients presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
- 20 Aug 2023 Results (n=84) assessing investigate rates, determinants and prognostic implications of triple regression in patients presenting with acute myocardial infarction (AMI) and treated with high-intensity lipid-lowering therapy published in the Journal of the American College of Cardiology